Potential Role of CMV in Restenosis Following Angioplasty, in Atherosclerosis, and in Endothelial Dysfunction - Full Text View

Sponsored by:	National Heart, Lung, and Blood Institute (NHLBI)
Information provided by:	National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:	NCT00001531

Purpose

The purpose of this study is to investigate whether the susceptibility of subjects to atherosclerosis is influenced by prior CMV exposure, whether the susceptability to endothelial dysfunction in patients with and in patients without atherosclerosis is influenced by prior CMV exposure.

Condition
Arterial Occlusive Diseases Atherosclerosis Coronary Disease Cytomegalovirus Infections

MedlinePlus related topics: Angioplasty Coronary Artery Disease Cytomegalovirus Infections

U.S. FDA Resources

Study Type:	Observational
Official Title:	Potential Role of CMV in Restenosis Following Angioplasty, in Atherosclerosis, and in Endothelial Dysfunction

Further study details as provided by National Institutes of Health Clinical Center (CC):

Estimated Enrollment:	355
Study Start Date:	June 1996
Estimated Study Completion Date:	September 2000

Detailed Description:

The purpose of this study is to investigate whether the susceptibility of subjects to atherosclerosis is influenced by prior CMV exposure, whether the susceptability to endothelial dysfunction in patients with and in patients without atherosclerosis is influenced by prior CMV exposure.

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Patients who are being evaluated to determine if they have CAD or those who have already been studied and the presence or absence of CAD has been ascertained.

No patients who have not been evaluated for CAD.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00001531

Locations

United States, Maryland
National Heart, Lung and Blood Institute (NHLBI)
Bethesda, Maryland, United States, 20892

Sponsors and Collaborators

National Heart, Lung, and Blood Institute (NHLBI)

More Information

Publications:

Speir E, Modali R, Huang ES, Leon MB, Shawl F, Finkel T, Epstein SE. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science. 1994 Jul 15;265(5170):391-4.

Schrier RD, Freeman WR, Wiley CA, McCutchan JA. Immune predispositions for cytomegalovirus retinitis in AIDS. The HNRC Group. J Clin Invest. 1995 Apr;95(4):1741-6.

Study ID Numbers:	960099, 96-H-0099
Study First Received:	November 3, 1999
Last Updated:	March 3, 2008
ClinicalTrials.gov Identifier:	NCT00001531
Health Authority:	United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):

Atherogenesis
Cell Mediated Immunity
Coronary Artery Disease

Study placed in the following topic categories:

Atherosclerosis
Arterial Occlusive Diseases
Heart Diseases
Myocardial Ischemia
Vascular Diseases
Arteriosclerosis
Ischemia
Cytomegalovirus

Herpesviridae Infections
Coronary Disease
Virus Diseases
Cytomegalovirus Infections
DNA Virus Infections
Cytomegalic inclusion disease
Coronary Artery Disease

Additional relevant MeSH terms:

Cardiovascular Diseases
Infection

ClinicalTrials.gov processed this record on January 15, 2009